Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7292   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-002280-34
    Sponsor's Protocol Code Number:1245.121
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-11-24
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-002280-34
    A.3Full title of the trial
    A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).
    Sperimentazione di fase III, randomizzata, in doppio cieco per valutare l¿efficacia e la sicurezza di empagliflozin 10 mg una volta al giorno rispetto al placebo, in pazienti affetti da insufficienza cardiaca cronica con frazione di eiezione ridotta (HFrEF).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure EMPEROR-Reduced
    Sperimentazione sul risultato di Empagliflozin in pazienti con insufficienza cardiaca cronica EMPEROR-Ridotta
    A.3.2Name or abbreviated title of the trial where available
    EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure EMPEROR-Reduced
    Sperimentazione sul risultato di Empagliflozin in pazienti con insufficienza cardiaca cronica EMPERO
    A.4.1Sponsor's protocol code number1245.121
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBOEHRINGER INGELHEIM INTERNATIONAL GMBH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBoehringer Ingelheim International GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBoehringer Ingelheim Pharma GmbH & Co. KG
    B.5.2Functional name of contact pointCT Disclosure & Data Transparency
    B.5.3 Address:
    B.5.3.1Street AddressBinger Strasse 173
    B.5.3.2Town/ cityIngelheim am Rhein
    B.5.3.3Post code55216
    B.5.3.4CountryGermany
    B.5.4Telephone number0018002430127
    B.5.5Fax number0018008217119
    B.5.6E-mailclintriage.rdg@boehringer-ingelheim.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name JARDIANCE - 10 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 14 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderBOEHRINGER INGELHEIM INTERNATIONAL GMBH
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEMPAGLIFLOZIN
    D.3.9.1CAS number 864070-44-0
    D.3.9.2Current sponsor codeEMPAGLIFLOZIN
    D.3.9.4EV Substance CodeSUB35915
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Heart failure (HF) with reduced ejection fraction (EF).
    Insufficienza cardiaca (HF) con frazione di eiezione (FE) ridotta.
    E.1.1.1Medical condition in easily understood language
    chronic (long-term) heart failure (HF)
    Insufficienza cardiaca (HF) cronica (di lunga durata)
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10008908
    E.1.2Term Chronic heart failure
    E.1.2System Organ Class 100000004849
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    to demonstrate superiority of empagliflozin 10 mg versus placebo on top of guideline-directed medical therapy in patients with symptomatic, chronic HF and reduced ejection fraction (LVEF = 40%).
    Dimostrare la superiorit¿ di empagliflozin 10 mg rispetto a placebo oltre alla terapia medica somministrata secondo le linee guida in pazienti affetti da insufficienza cardiaca (HF) cronica con frazione di eiezione del ventricolo sinistro ridotta (FEVS =40%).
    E.2.2Secondary objectives of the trial
    Not applicable
    Non applicabile
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: Drug concentration measurements and Pharmacokinetics (PK) substudy: PK sampling will be done from a limited number of randomised patients (approx 1140) at sites in pre-selected Countries. Pre-dose blood samples will be collected at Visit 4 and between 22 to 26 h after the most recent drug
    intake, to determine plasma empagliflozin trough concentrations. These samples will serve to determine steady state trough concentrations of
    empagliflozin.
    Optional Banking sub-study requiring samples collection at visit 2, 4 and 8 (plasma, serum, urine) and visit 2 (DNA).

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: Le misurazioni di concentrazione del farmaco e il sottostudio sulla farmacocinetica (PK): la raccolta di campioni per la farmacocinetica (PK) sara¿ fatta su un numero limitato di pazienti randaomizzati (circa 1140) e ai centri in Paesi preselezionati.. Campioni di sangue pre-dosati saranno raccolti alla Visita 4 e tra la le 22 e 26 ore dopo l'ultima assunzione del farmaco, per la determinazione del plasma empagliflozin allo stato stazionario.
    Sottostudio facoltativo di Biobanking che richiede Ia raccolta di campioni alle visite 2, 4 e 8 (plasma, siero, urina) e Visit 2 (DNA).
    E.3Principal inclusion criteria
    - Patients with chronic HF diagnosed for at least 3 months before Visit 1 and currently in HF New York Heart Association (NYHA)class II-IV
    - Chronic HF with reduced EF defined as LVEF = 40% per local reading (obtained under stable condition by echocardiography, radionuclide ventriculography, invasive angiography, MRI or CT). A previous LVEF can be used if it is measured within 6 months from visit 1 or can be measured after obtaining the informed consent to the study. LVEF must be documented in an official report before randomization.
    - Besides LVEF minor or equal to 40%, patients must have at least one of the following evidence of HF:
    a) If EF =36% to =40%: Elevated NT-proBNP at Visit 1 =2500 pg/ml for patients without AF, OR =5000 pg/ml for patients with AF, analysed at the Central Laboratory,
    b) If EF =31% to =35%: Elevated NT-proBNP at Visit 1 =1000 pg/ml for patients without AF, OR =2000 pg/ml for patients with AF, analysed at the Central Laboratory,
    c) If EF=30%: Elevated NT-proBNP at Visit 1 =600 pg/ml for patients without AF, OR =1200 pg/ml for patients with AF, analysed at the Central Laboratory
    d) If EF < 40% and HHF documented in the 12 months prior to visit 1, and high levels of NT-proBNP at visit 1, > 1.600 pg/ml for patients without AF OR > 1.200 pg/ml for patients with AF, analysed at central laboratory
    - Appropriate dose of medical therapy for HF (such as ACEi, ARB, ß-blocker, oral diuretics, MRA, ARNI, ivabradine) consistent with prevailing local and international CV guidelines, stable for at least 1 week prior to Visit 1 and during screening period until Visit 2 with exception of diuretics stable for only one week prior to Visit 2 to control symptoms.

    - Appropriate use of medical devices such as cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) consistent with prevailing local or international CV guidelines, unless implanted within 3 months prior Visit 1, or if intent to implant ICD or CRT
    8. Body Mass Index < 45 kg/m2 at Visit 1.
    • Pazienti con HF cronica diagnosticata da almeno 3 mesi prima della Visita 1 e attualmente in HF di classe II-IV secondo la New York Heart Association (NYHA).
    • HF cronica con FE ridotta definita come FEVS =40% secondo la lettura locale (ottenuta in condizioni stabili tramite ecocardiografia, ventricolografia con radionuclidi, angiografia invasiva, risonanza magnetica [RMI] o tomografia assiale computerizzata [TAC]). Un’anamnesi di frazione di eiezione del ventricolo
    sinistro (LVEF) puô essere utilizzata purché sia stata misurata nei 6 mesi precedenti Ia Visita 1 oppure puô essere misurata una volta ottenuto il consenso per Ia studio. La LVEF deve essere documentata in un referto ufficiale prima della randomizzazione.
    • Oltre alla LVEF minore o uguale a 40%,I pazienti devono presentare almeno una delle seguenti evidenze di HF:
    - In caso di FE da =36 a =40: livelli elevati di N-terminale-pro-peptide natriuretico cerebrale (NT-proBNP) alla Visita 1 =2.500 pg/ml per i pazienti senza FA OPPURE =5.000 pg/ml per i pazienti affetti da fibrillazione atriale (FA), analizzati presso il laboratorio centrale,
    - In caso di FE da =31 a =35: livelli elevati di NT-proBNP alla Visita 1 =1.000 pg/ml per i pazienti senza FA OPPURE =2.000 pg/ml per i pazienti affetti da FA, analizzati presso il laboratorio centrale,
    - In caso di FE =30%: livelli elevati di NT-proBNP alla Visita 1 =600 pg/ml per i pazienti senza FA OPPURE =1.200 pg/ml per i pazienti affetti da FA, analizzati presso il laboratorio centrale
    - In caso di FE <40% e HHF documentate nei 12 mesi precedenti Ia Visita 1, e livelli elevati di NT-proBNP alla Visita 1 600 pg/ml per i pazienti senza FA OPPURE 1.200 pg/mi per i pazienti affetti da FA, analizzati presso ii laboratorio centrale
    • Adeguata dose di terapia medica per HF (quali inibitori dell’enzima di conversione dell’angiotensina [ACEi], bloccanti del recettore dell’angiotensina [ARB], ß-bloccanti, diuretici orali, antagonisti del recettore dei mineralcorticoidi [MRA], inibitori del recettore dell’angiotensina e della neprilisina [ARNI], ivabradina) e terapia con opportuno dispositivo, somministrate in conformità alle attuali linee guida cardiovascolari (CV) e in maniera stabile da almeno 1 settimana prima della Visita 1 (screening) e durante il periodo di screening fino alla Visita 2 (randomizzazione), ad eccezione dei diuretici che devono essere stabili soltanto da una settimana prima della Visita 2 per controllare i sintomi. Lo sperimentatore deve documentare il motivo per cui il paziente non sta assumendo la dose target secondo le linee guida locali.

    • Uso appropriato di dispositivi medici, quali defibrillatore cardioverter impiantabile (ICD) o una terapia di resincronizzazione cardiaca (CRT), in conformità alle linee guida CV predominanti a livello locale o internazionale, a meno che il dispositivo non sia stato impiantato nei 3 mesi precedenti la Visita 1 o qualora vi sia l’intenzione di impiantare un ICD o somministrare una CRT
    • Velocità stimata di filtrazione glomerulare (eGFR) =20 ml/min/1,73 m2 alla Visita 1.
    E.4Principal exclusion criteria
    1. Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischaemia or newly developed ischaemic ECG changes), coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or TIA in past 90 days prior to Visit 1
    2. Heart transplant recipient, or listed for heart transplant
    3. Currently implanted left ventricular assist device (LVAD)
    4. Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy or known pericardial constriction
    5. Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial in the investigator’s opinion
    6. Acute decompensated HF (exacerbation of chronic HF) requiring i.v. diuretics, i.v. inotropes, or i.v. vasodilators, or LVAD within 1 week from discharge to Visit 1 (Screening) and during screening period until Visit 2 (Randomisation)

    7. Atrial fibrillation or atrial flutter with a resting heart rate >110 bpm documented by ECG at Visit 2 (Randomisation)
    8. Untreated ventricular arrhythmia with syncope in patients without ICD documented within the 3 months prior to Visit 1
    9. Diagnosis of cardiomyopathy induced by chemotherapy or peripartum within the 12 months prior to Visit 1
    10. Symptomatic bradycardia or second or third degree heart block without a pacemaker after adjusting beta-blocker therapy, if appropriate
    1. Iinfarto miocardico (aumento degli enzimi cardiaci in combinazione con sintomi di ischemia o cambiamenti ischemici all'ECG di nuova concezione), chirurgia del trapianto di bypass coronarico, o altri interventi di chirurgia cardiovascolare, ictus o TIA negli ultimi 90 giorni antecedenti la visita 1
    2. Destinatario di trapianto di cuore, o in lista per trapianto di cuore
    3. Attualmente impiantato un dispositivo di assistenza ventricolare sinistra (LVAD)
    4. Cardiomiopatia sulla base di malattie infiltrative (ad esempio amiloidosi), malattie di accumulo (per esempio emocromatosi, malattia di Fabry), distrofie muscolari, cardiomiopatia con cause reversibili (ad esempio cardiomiopatia da stress), cardiomiopatia ipertrofica ostruttiva o conosciuto costrizione pericardica
    5. Qualsiasi malattia grave (ostruttiva o rigurgito) delle valvole cardiache, che dovrebbe portare ad un intervento chirurgico durante la sperimentazione secondo il giudizio dello sperimentatore
    6. Insufficienza cardiaca acuta scompensata (esacerbazione di scompenso cardiaco cronico) che richiedono diuretici intravenosi, inotropi intravenosi, o vasodilatatori intravenosi, o LVAD entro 1 settimana dallo scaricamento alla Visita 1 (screening) e durante il periodo di screening fino Visita 2 (randomizzazione)
    7. Fibrillazione atriale o flutter atriale con una frequenza cardiaca a riposo> 110 bpm documentata da ECG alla Visita 2 (randomizzazione)
    8. Aritmia ventricolare con sincope non trattata in pazienti senza ICD documentata entro i 3 mesi precedenti la visita 1
    9. La diagnosi di cardiomiopatia indotta da chemioterapia o peri-parto entro i 12 mesi precedenti la visita 1
    10. bradicardia sintomatica o arresto cardiaco di secondo o terzo grado senza un pacemaker dopo aver regolato la terapia con beta-bloccanti, se appropriato
    E.5 End points
    E.5.1Primary end point(s)
    Time to first event of adjudicated CV death or adjudicated HHF in patients with Heart Failure with reduced Ejection Fraction (HFrEF).
    L’endpoint primario composito per questa sperimentazione è il tempo al primo evento di decesso CV convalidato od ospedalizzazione per HF (HHF) convalidata in pazienti affetti da HFrEF.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Report time to event
    Tempo di reportistica dell'evento
    E.5.2Secondary end point(s)
    1. Occurrence of adjudicated HHF (first and recurrent),
    2. eGFR (CKD-EPI)cr slope of change from baseline
    - Time to first occurrence of chronic dialysis or kidney transplant or sustained reduction of =40% eGFR (CKDEPI)
    or
    a) sustained eGFR (CKD-EPI)cr <15 mL/min/1.73 m2 for patients with baseline eGFR =30 mL/min/1.73 m2
    b) sustained eGFR (CKD-EPI)cr <10 mL/min/1.73 m2 for patients with baseline eGFR <30 mL/min/1.73 m2
    Chronic dialysis is defined as a dialysis with a frequency of twice a week or more for at least 90 days
    - Time to first adjudicated HHF
    - Time to adjudicated CV death
    - Time to all-cause mortality
    - Time to onset of DM (defined as HbA1c =6.5% or as diagnosed by the Investigator) in patients with pre- DM defined as no history of DM and no HbA1c =6.5 before treatment, and a pre-treatment HbA1c value of = 5.7 and <6.5
    - Change from baseline in clinical summary score (HF symptoms and physical limitations domains) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) at week 52
    - Occurrence of all-cause hospitalisation (first and recurrent)
    ¿ Episodio di HHF convalidata (primo e ricorrente)
    ¿ Pendenza della variazione rispetto al basale nell¿eGFR (misurata mediante l¿equazione della Collaborazione per l¿epidemiologia della malattia renale cronica [CKD-EPI])cr
    ¿ Tempo alla prima manifestazione di dialisi cronica o trapianto renale o riduzione sostenuta dell¿eGFR (CKD-EPI)cr =40% o
    o eGFR (CKD-EPI)cr sostenuta <15 ml/min/1,73 m2 per i pazienti con eGFR al basale =30 ml/min/1,73 m2
    o eGFR (CKD-EPI)cr sostenuta <10 ml/min/1,73 m2 per i pazienti con eGFR al basale <30 ml/min/1,73 m2
    La dialisi cronica è definita come dialisi con una frequenza di due volte a settimana o piü spesso per almeno 90 giorni
    ¿ Tempo alla prima HHF convalidata
    ¿ Tempo al decesso CV convalidato
    ¿ Tempo al decesso per qualsiasi causa
    ¿ Tempo all¿insorgenza di diabete mellito (DM) in pazienti con pre-DM
    ¿ Variazione rispetto al basale del punteggio clinico riepilogativo (sintomi di HF e domini di limitazioni fisiche) del Questionario di cardiomiopatia di Kansas City (KCCQ) alla settimana 52
    ¿ Episodio di ricovero per qualsiasi causa (primo e ricorrente)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Report time to event
    Tempo di reportistica dell'evento
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned11
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA152
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Brazil
    Canada
    China
    Colombia
    European Union
    India
    Japan
    Korea, Republic of
    Mexico
    Singapore
    South Africa
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1425
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 1425
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state90
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1114
    F.4.2.2In the whole clinical trial 2850
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The patient will continue treatment according to standard of care and prevailing guidelines.
    Il paziente continuer¿ il trattamento in base alle cure standard e alle linee guida prevalenti.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-08-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-06-22
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-05-28
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 06 21:46:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA